查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
生物防禦市場規模、份額和趨勢分析報告：按產品（炭疽、天花、肉毒桿菌、輻射/核）、地區（北美、歐洲、亞太地區）、分部預測，2023-2030 年
市場調查報告書
商品編碼
1178739

生物防禦市場規模、份額和趨勢分析報告：按產品（炭疽、天花、肉毒桿菌、輻射/核）、地區（北美、歐洲、亞太地區）、分部預測，2023-2030 年

Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear), By Region (North America, Europe, APAC), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

生物防禦市場增長和趨勢

根據 Grand View Research, Inc. 的一份新報告，到 2030 年，全球生物防禦市場規模預計將達到 228 億美元，從 2022 年到 2030 年的複合年增長率為 5.0%。 生物防禦可以簡潔地定義為為恢復一個國家的生物安全而採取的一套綜合措施（識別、規劃和準備）。

它旨在解決重大生物威脅和傳染病，這些威脅和傳染病很容易被用作生物武器來煽動內亂和生物恐怖主義。 生物威脅，無論是自然的、意外的還是故意的，都是各種形式的重大威脅。 積極的政府舉措、私營公司增加投資以及各種病毒的傳播等因素正在推動市場的增長。

由於過去炭疽、天花和肉毒梭菌等病毒病原體的生物恐怖主義襲擊，生物防禦已成為一個主要的重點領域。 各國越來越需要取得進展以保護自己免受嚴重威脅，這仍然是增長的關鍵驅動力。 2017 年，美國疾病控制與預防中心 (CDC) 表示，它追蹤了 190 多個國家的 170 多種地方病和疫情。

據世界衛生組織稱，每年約有 6,500,000 人死於與季節性流感相關的呼吸道疾病。 寨卡病毒和埃博拉病毒的反復爆發迫使州政府制定生物防禦計劃並製定戰略。 這些新計劃將有助於規劃和應對未來的疫情。

2018 年，美國政府宣布了一項國家生物防禦戰略，以管理生物威脅的風險。 這種新策略可以從源頭檢測並遏制生物威脅，同時促進生物醫學創新並改進應急響應。 預計這些因素將推動市場的增長。

生物防禦市場報告要點

到 2022 年，炭疽細分市場將主導市場。 這些生物試劑在環境中的存留時間更長，並且容易釋放，因此具有更高的潛在風險

其他部分預計在預測期內的複合年增長率最高。 該部分包括寨卡病毒、埃博拉病毒和馬爾堡病毒等潛在威脅。 相關疫情的增加仍然是主要的增長動力。

由於聯邦政府提供了大量資金、技術進步和公眾意識的提高，預計在預測期內北美將主導全球市場。

內容

第1章調查方法及範圍

  • 市場細分和範圍
    • 產品
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查的詳細信息
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析（模型 1）
  • 次要信息列表
  • 主要信息列表
  • 縮寫列表
  • 目的

第 2 章執行摘要

  • 市場前景

第 3 章生物防禦市場：變量、趨勢和範圍

  • 市場細分和範圍
  • 市場動態
    • 市場驅動因素分析
    • 在美國存在有利的政府舉措
      • 2016-2021 年聯邦機構生物防禦基金
      • 醫療產品緊急使用授權
      • 項目生物防護法
      • 私營企業的投資增加
    • 埃博拉病毒、寨卡病毒和流感等各種病原體的傳播
    • 市場製約因素分析
      • 在發展中國家和發展中國家的市場滲透率低
  • 描繪滲透率和增長前景
  • Biodefense：一種市場分析工具
    • 行業分析 - 搬運工
    • PESTEL 分析
  • 生物防禦競爭情景，2015 年
    • 生物防禦
      • 生物防禦：產品管線
    • 化學防禦
      • 化學防禦：產品管道
    • 核與輻射防護
      • 核與輻射防護：產品管道分析

第 4 章生物防禦市場：產品細分分析

  • 生物防禦：2022 年和 2030 年市場份額分析
  • 炭疽桿菌
  • 天花
  • 肉毒中毒
  • 輻射/核能
    • 其他
      • 其他生物防禦產品市場，2018-2030 年（百萬美元）

第 5 章生物防禦市場：區域分析

  • 生物防禦：區域市場份額分析，2022 年和 2030 年
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 多邊環境協定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第6章公司簡介

  • Xoma 公司
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Altimmune, Inc.
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Emergent Biosolutions Inc.
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Dynavax 技術公司
    • 公司簡介
    • 財務業績
    • 戰略舉措
  • Siga Technologies, Inc.
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Elusys Therapeutics, Inc.
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Ichor 醫療系統
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Dynport 疫苗有限公司
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • 克利夫蘭生物實驗室
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • 巴伐利亞北歐人
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Ology Bioservices
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Alnylam Pharmaceuticals, Inc.
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
Product Code: 978-1-68038-313-3

Biodefense Market Growth & Trends:

The global biodefense market size is expected to reach USD 22.8 billion by 2030, and it is set to expand at 5.0% CAGR from 2022 to 2030, according to a new report by Grand View Research, Inc. Biodefense can be briefly defined as a set of comprehensive measures (identification, planning, and preparedness) undertaken to restore the biosecurity of a country.

It aims to tackle key biological threats or infectious diseases that can be easily used as a bioweapon to instigate social unrest and bioterrorism. Biological threats can be natural, accidental, or deliberate in origin and in all forms, present a grave threat. Factors like the presence of favorable government initiatives, increasing investment by private players, and the growing prevalence of various viral agents are fueling market growth.

Previous incidents of bioterrorism caused by viral agents like anthrax, smallpox, and botulism have made Biodefense a major focus area. The increased need for advancements for countries to defend themselves against grave threats remains the primary driver of growth. In 2017, the Centers for Disease Control and Prevention (CDC) stated that they had tracked more than 170 unique diseases, and outbreaks in more than 190 countries.

According to WHO, around 6,50,000 people die of respiratory diseases associated with seasonal flu annually. Repeated outbreaks of Zika and Ebola virus have coerced state governments to construct and strategize biodefense programs. These new programs will assist in planning and response during future outbreaks.

In 2018, the U.S. government announced a national biodefense strategy to manage the risk of biological threats. The new strategy can detect and contain bio-threats at its source, while simultaneously promoting biomedical innovation, and improving emergency response. These factors are expected to boost market growth.

Biodefense Market Report Highlights:

  • The anthrax segment dominated the market in 2022. These bioagents can last longer in the environment, and are released with ease, posing a high potential risk
  • The other segment is expected to register the highest CAGR during the forecast period. This segment includes potential threats such as zika, Ebola, and Marburg's virus. The rising incidents of related outbreaks remain the key growth driver
  • North America is expected to dominate the global market during the forecast period, owing to the presence of high federal funding, technological advancements, and growing awareness among the population

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Product
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Primary Sources
  • 1.9 List Of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1
    • 1.10.2 Objective - 2
    • 1.10.3 Objective - 3
    • 1.10.4 Objective - 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Biodefence Market: Variables, Trends, & Scope

  • 3.1 Market Segmentation And Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
    • 3.2.2 Presence Of Favorable Government Initiatives In The U.S.
      • 3.2.2.1 Biodefense Funding In Fy 2016 - 2021 By Federal Agency
      • 3.2.2.2 Emergency Use Authorization Of Medical Products
      • 3.2.2.3 Project Bioshield Act
      • 3.2.2.4 Growing Investment From Private Players
    • 3.2.3 Growing Prevalence Of Various Agents Such As Ebola Virus, Zika Virus, Flu, And Others
    • 3.2.4 Market Restraint Analysis
      • 3.2.4.1 Low Market Penetration In Developing And Underdeveloped Countries
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 Biodefence: Market Analysis Tools
    • 3.4.1 Industry Analysis - Porter's
    • 3.4.2 Pestel Analysis
  • 3.5 Biodefense Competitive Scenario, 2015
    • 3.5.1 Biological Defense
      • 3.5.1.1 Biological Defense: Product Pipeline
    • 3.5.2 Chemical Defense
      • 3.5.2.1 Chemical Defense: Product Pipeline
    • 3.5.3 Nuclear/Radiological Defense
      • 3.5.3.1 Nuclear/Radiological Defense: Product Pipeline Analysis

Chapter 4 Biodefence Market: Product Segment Analysis

  • 4.1 Biodefence: Agent Market Share Analysis, 2022 & 2030
  • 4.2 Anthrax
    • 4.2.1 Biodefense Against Anthrax Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.3 Smallpox
    • 4.3.1 Biodefense Against Smallpox Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.4 Botulism
    • 4.4.1 Biodefense Against Botulism Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.5 Radiation/Nuclear
    • 4.5.1 Biodefense Against Radiation/Nuclear Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2 Others
      • 4.5.2.1 Other Biodefense Products Market, 2018 - 2030 (USD Million)

Chapter 5 Biodefence Market: Regional Analysis

  • 5.1 Biodefence: Regional Market Share Analysis, 2022 & 2030
  • 5.2 North America
    • 5.2.1 North America Biodefence Market, 2018 - 2030 (USD Million)
    • 5.2.2 U.S.
      • 5.2.2.1 U.S. Biodefence Market, 2018 - 2030 (USD Million)
    • 5.2.3 Canada
      • 5.2.3.1 Canada Biodefence Market, 2018 - 2030 (USD Million)
  • 5.3 Europe
    • 5.3.1 Europe Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.2 U.K.
      • 5.3.2.1 U.K. Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.3 Germany
      • 5.3.3.1 Germany Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.4 France
      • 5.3.4.1 France Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.5 Italy
      • 5.3.5.1 Italy Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.6 Spain
      • 5.3.6.1 Spain Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.7 Denmark
      • 5.3.7.1 Denmark Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.8 Sweden
      • 5.3.8.1 Spain Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.9 Norway
      • 5.3.9.1 Norway Biodefence Market, 2018 - 2030 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.2 China
      • 5.4.2.1 China Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.3 India
      • 5.4.3.1 India Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.4 Japan
      • 5.4.4.1 Japan Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.5 Australia
      • 5.4.5.1 Australia Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.6 Thailand
      • 5.4.6.1 Thailand Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.7 South Korea
      • 5.4.7.1 South Korea Biodefence Market, 2018 - 2030 (USD Million)
  • 5.5 Latin America
    • 5.5.1 Latin America Biodefence Market, 2018 - 2030 (USD Million)
    • 5.5.2 Brazil
      • 5.5.2.1 Brazil Biodefence Market, 2018 - 2030 (USD Million)
    • 5.5.3 Mexico
      • 5.5.3.1 Mexico Biodefence Market, 2018 - 2030 (USD Million)
    • 5.5.4 Argentina
      • 5.5.4.1 Argentina Biodefence Market, 2018 - 2030 (USD Million)
  • 5.6 MEA
    • 5.6.1 MEA Biodefence Market, 2018 - 2030 (USD Million)
    • 5.6.2 South Africa
      • 5.6.2.1 South Africa Biodefence Market, 2018 - 2030 (USD Million)
    • 5.6.3 Saudi Arabia
      • 5.6.3.1 Saudi Arabia Biodefence Market, 2018 - 2030 (USD Million)
    • 5.6.4 UAE
      • 5.6.4.1 UAE Biodefence Market, 2018 - 2030 (USD Million)
    • 5.6.5 Kuwait
      • 5.6.5.1 Kuwait Biodefence Market, 2018 - 2030 (USD Million)

Chapter 6 Company Profiles

    • 6.1.1 Xoma Corporation
      • 6.1.1.1 Company Overview
      • 6.1.1.2 Financial Performance
      • 6.1.1.3 Product Benchmarking
      • 6.1.1.4 Strategic Initiatives
    • 6.1.2 Altimmune, Inc.
      • 6.1.2.1 Company Overview
      • 6.1.2.2 Financial Performance
      • 6.1.2.3 Product Benchmarking
      • 6.1.2.4 Strategic Initiatives
    • 6.1.3 Emergent Biosolutions Inc.
      • 6.1.3.1 Company Overview
      • 6.1.3.2 Financial Performance
      • 6.1.3.3 Product Benchmarking
      • 6.1.3.4 Strategic Initiatives
    • 6.1.4 Dynavax Technologies Corporation
      • 6.1.4.1 Company Overview
      • 6.1.4.2 Financial Performance
      • 6.1.4.3 Strategic Initiatives
    • 6.1.5 Siga Technologies, Inc.
      • 6.1.5.1 Company Overview
      • 6.1.5.2 Financial Performance
      • 6.1.5.3 Product Benchmarking
      • 6.1.5.4 Strategic Initiatives
    • 6.1.6 Elusys Therapeutics, Inc.
      • 6.1.6.1 Company Overview
      • 6.1.6.2 Financial Performance
      • 6.1.6.3 Product Benchmarking
      • 6.1.6.4 Strategic Initiatives
    • 6.1.7 Ichor Medical Systems
      • 6.1.7.1 Company Overview
      • 6.1.7.2 Financial Performance
      • 6.1.7.3 Product Benchmarking
      • 6.1.7.4 Strategic Initiatives
    • 6.1.8 Dynport Vaccine Company Llc
      • 6.1.8.1 Company Overview
      • 6.1.8.2 Financial Performance
      • 6.1.8.3 Product Benchmarking
      • 6.1.8.4 Strategic Initiatives
    • 6.1.9 Cleveland Biolabs
      • 6.1.9.1 Company Overview
      • 6.1.9.2 Financial Performance
      • 6.1.9.3 Product Benchmarking
      • 6.1.9.4 Strategic Initiatives
    • 6.1.10 Bavarian Nordic
      • 6.1.10.1 Company Overview
      • 6.1.10.2 Financial Performance
      • 6.1.10.3 Product Benchmarking
      • 6.1.10.4 Strategic Initiatives
    • 6.1.11 Ology Bioservices
      • 6.1.11.1 Company Overview
      • 6.1.11.2 Financial Performance
      • 6.1.11.3 Product Benchmarking
      • 6.1.11.4 Strategic Initiatives
    • 6.1.12 Alnylam Pharmaceuticals, Inc.
      • 6.1.12.1 Company Overview
      • 6.1.12.2 Financial Performance
      • 6.1.12.3 Product Benchmarking
      • 6.1.12.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. government civilian biodefense funding, by agencies for the years 2017 - 2019 in USD Million.
  • Table 4 National Institutes of Health Funding for the years 2017 - 2019 in USD Million
  • Table 5 Travel Associated cases of Zika Virus in the U.S in 2019
  • Table 6 Ebola Funding to WHO, 2019

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Biodefence market snapshot (2022)
  • Fig. 10 Biodefence market segmentation
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 16 Biodefence market product type outlook: Segment dashboard
  • Fig. 17 Biodefence market: Product movement analysis
  • Fig. 18 Anthrax market, 2018 - 2030 (USD Million)
  • Fig. 19 Smallpox market, 2018 - 2030 (USD Million)
  • Fig. 20 Botulism market, 2018 - 2030 (USD Million)
  • Fig. 21 Radiation and Nuclear market, 2018 - 2030 (USD Million)
  • Fig. 22 Others market, 2018 - 2030 (USD Million)
  • Fig. 23 Regional market: Key takeaways
  • Fig. 24 Regional outlook, 2022 & 2030
  • Fig. 25 North America market, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 27 Canada market, 2018 - 2030 (USD Million)
  • Fig. 28 Europe market, 2018 - 2030 (USD Million)
  • Fig. 29 U.K. market, 2018 - 2030 (USD Million)
  • Fig. 30 Germany market, 2018 - 2030 (USD Million)
  • Fig. 31 France market, 2018 - 2030 (USD Million)
  • Fig. 32 Italy market, 2018 - 2030 (USD Million)
  • Fig. 33 Spain market, 2018 - 2030 (USD Million)
  • Fig. 34 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 35 China market, 2018 - 2030 (USD Million)
  • Fig. 36 India market, 2018 - 2030 (USD Million)
  • Fig. 37 Japan market, 2018 - 2030 (USD Million)
  • Fig. 38 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 39 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 41 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 42 MEA market, 2018 - 2030 (USD Million)
  • Fig. 43 South Africa market, 2018 - 2030 (USD Million)